- Home
- BHIL vs NXTC Comparison
BHIL vs NXTC Comparison
Compare BHIL & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BHIL
- NXTC
- Stock Information
- Founded
- BHIL 2012
- NXTC 2015
- Country
- BHIL United States
- NXTC United States
- Employees
- BHIL N/A
- NXTC N/A
- Industry
- BHIL Packaged Foods
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- BHIL Consumer Staples
- NXTC Health Care
- Exchange
- BHIL Nasdaq
- NXTC Nasdaq
- Market Cap
- BHIL 27.1M
- NXTC 31.6M
- IPO Year
- BHIL N/A
- NXTC 2019
- Fundamental
- Price
- BHIL $2.69
- NXTC $0.97
- Analyst Decision
- BHIL
- NXTC Strong Buy
- Analyst Count
- BHIL 0
- NXTC 2
- Target Price
- BHIL N/A
- NXTC $4.00
- AVG Volume (30 Days)
- BHIL 35.4K
- NXTC 222.9K
- Earning Date
- BHIL 11-12-2024
- NXTC 11-07-2024
- Dividend Yield
- BHIL N/A
- NXTC N/A
- EPS Growth
- BHIL N/A
- NXTC N/A
- EPS
- BHIL N/A
- NXTC N/A
- Revenue
- BHIL $466,725,000.00
- NXTC N/A
- Revenue This Year
- BHIL N/A
- NXTC N/A
- Revenue Next Year
- BHIL N/A
- NXTC N/A
- P/E Ratio
- BHIL N/A
- NXTC N/A
- Revenue Growth
- BHIL 139.60
- NXTC N/A
- 52 Week Low
- BHIL $1.86
- NXTC $0.87
- 52 Week High
- BHIL $11.03
- NXTC $2.57
- Technical
- Relative Strength Index (RSI)
- BHIL 35.35
- NXTC 34.08
- Support Level
- BHIL $1.86
- NXTC $0.87
- Resistance Level
- BHIL $3.17
- NXTC $1.00
- Average True Range (ATR)
- BHIL 0.38
- NXTC 0.11
- MACD
- BHIL 0.10
- NXTC -0.01
- Stochastic Oscillator
- BHIL 48.55
- NXTC 26.32
About BHIL Benson Hill Inc.
Benson Hill Inc is an ag-tech company specializing in soy protein innovation. The company has one business segment Ingredient. The company focuses on seed innovation through proprietary germplasm and the CropOS platform. This platform integrates protein, genomic, and strategic data for predictive breeding using AI and ML. They operate a Crop Accelerator for rapid prototyping. Benson Hill is developing a seed portfolio for protein ingredients, aquaculture, specialty animal feed, and vegetable oils. The company's revenue can be disaggregated into product categories: Proprietary and Non-Proprietary. Proprietary revenue is defined as any sale of a proprietary bean. Non-Proprietary revenue is all other revenue from non-Proprietary sources.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases, and NC181, for Alzheimer's disease.